Core Viewpoint - The article emphasizes the potential of biomanufacturing as a strategic avenue for China to achieve a "leapfrog" in high-end manufacturing, similar to the advancements seen in the renewable energy sector, with a market scale projected to exceed one trillion yuan [3][4]. Group 1: Biomanufacturing Overview - Biomanufacturing is gaining attention due to its mention in the "14th Five-Year Plan," highlighting its importance for China's industrial strategy [3]. - The global market for biobased products is expected to exceed $800 billion by 2030, with at least 20% of petrochemical products being replaced by biobased alternatives [3][4]. - The integration of biomanufacturing into existing industrial systems is crucial for its success, as it should not exist in isolation but rather enhance current supply chains [4]. Group 2: Company Development - SiPeng Technology was founded in 2022 by Tao Fei and Xu Ping, with total financing exceeding 100 million yuan from various investors [6][11]. - The company has developed a unique microbial platform using cyanobacteria, which can utilize carbon dioxide to produce materials, fuels, and high-value compounds [8][10]. - SiPeng's ultimate goal is to apply carbon-negative biomanufacturing technologies to sustainable production of bulk products, thereby reducing carbon emissions and pollution [13]. Group 3: Technological Advancements - The company is focused on the third generation of biomanufacturing, which utilizes atmospheric carbon dioxide as a raw material, potentially leading to cost reductions and sustainable practices [15][17]. - SiPeng has established a proprietary cell library and employs AI to enhance the design and production processes, significantly improving research and development efficiency [19]. - The transition from laboratory-scale production to industrial-scale manufacturing is a critical challenge, which SiPeng aims to overcome through innovative engineering and design strategies [18][20]. Group 4: Product Applications - SiPeng's biobased materials are versatile, suitable for applications in food packaging, stationery, cosmetics, sports equipment, and automotive parts [22]. - The company has successfully developed high-performance biobased products, such as a biodegradable PLA-based T-shirt, which is both environmentally friendly and offers superior user experience [22]. - Collaboration with other companies, such as Tianwu Technology, aims to enhance product performance through AI-driven protein modification [23].

在全球推进绿色转型与"双碳"目标的战略背景下，生物基化学品与材料作为生物制造产业的核心支 柱，凭借原料可再生、全生命周期低碳环保等核心优势，正加速替代传统石油基产品，在包装、纺 织、汽车等领域展现出广阔应用前景，成为全球产业绿色转型的关键赛道。 我国高度重视该领域发展，将生物基新材料列为关键战略材料，多项产业扶持政策持续落地。然 而，产业仍面临包括综合成本竞争力、原料供应链稳定、产品性能优化及终端市场接受度等关键问 题。 基于此， 2026年3月31日-4月1日 ，"第五届中国合成生物学及生物制造大会"将在杭州举办，其中设 置 【 生物基化学品与材料专场】 ，旨在汇聚产学研用多方智慧，破解产业发展难题，助力生物基 化学品与材料产业高质量发展。 大会介绍 0 1 大会时间 | 2026年3月31日-4月1日 大会地点 | 杭州市 大会规模 | 1000人 主办单位 | synbio深波 扫码 免费 报名参会 ↓↓↓ 论坛设置 0 2 拟定话题 0 3 *以大会现场实际议程为准 会议路演报名（审核制） 请添加下方微信，备注 "报名路演" 商务合作 0 4 生物基大宗化学品的绿色生物制造 基于合成生物技术的分子和材 ...

Core Insights - The establishment of MYCO ONE Global marks a significant step towards sustainable transformation in the global food industry, focusing on the development and commercialization of mycoprotein-based products [1][10] - The partnership aims to leverage the strengths of both companies to meet the growing demand for sustainable and healthy protein solutions in the market [10] Company Overview - MYCO ONE Global is a joint venture between 富祥药业's wholly-owned subsidiary in Singapore and MYCO ONE d.o.o., an innovative food company based in Slovenia [1] - The company will focus on the development, production, and marketing of mycoprotein products, particularly the "未冉蛋白" [1][2] Product Development - The core product, "未冉蛋白," is a mycoprotein derived from filamentous fungi, recognized for its high protein content and nutritional benefits, including 18 essential amino acids and dietary fiber [2] - The product is free from antibiotics, pesticide residues, and hormones, ensuring food safety and health for consumers [2] Market Strategy - MYCO ONE Global plans to penetrate mainstream retail channels in Europe, including major supermarket chains such as ALDI, SPAR, Kaufland, and Metro [4] - The company aims to expand its market presence from Europe to the Americas and Asia, providing high-nutrition, sustainable mycoprotein ingredients and customized applications [4][12] Product Launch - The initial product offerings will include MYCO Juicy Burger (beef flavor) and MYCO Chicky Burger (chicken flavor), designed to enhance the sensory experience while maintaining health attributes [5][7] - The MYCO Juicy Burger has received a high sensory evaluation score of 18.6 out of 20, indicating its readiness for mainstream retail [7] Strategic Implications - This collaboration represents a significant integration of Chinese fermentation technology with European food branding and distribution systems, addressing global consumer demands for healthy and sustainable protein sources [10] - The establishment of MYCO ONE Global signifies a strategic shift for 富祥药业 from a raw material producer to a global player in food technology, leveraging its expertise in microbial fermentation [12]

Core Viewpoint - The article discusses the key deployments in the 2023 Central Document No. 1, focusing on agricultural modernization through technological innovation and the development of new productive forces in agriculture [5][6][7]. Group 1: Key Deployments in Agricultural Technology Innovation - The document emphasizes strengthening integrated innovation by enhancing the overall effectiveness of the agricultural technology innovation system, promoting enterprise-led innovation, and focusing on key areas such as seeds and agricultural machinery [5]. - It highlights the expansion of application scenarios through modern information technology and biotechnology, showcasing the significant role of agricultural drones and artificial intelligence in transforming agricultural practices [6]. - The document stresses the importance of promoting the transformation of agricultural technology achievements to address practical issues faced by farmers, ensuring that innovations reach rural areas effectively [7]. Group 2: Agricultural Bio-Manufacturing Paths Worth Noting - The article identifies high-value utilization of agricultural by-products, such as straw, as a key focus, indicating a shift from mere utilization to profitable applications [8]. - It discusses the potential of synthetic biology to enhance agricultural productivity by producing essential proteins and bio-fertilizers, thereby reducing reliance on chemical fertilizers [10]. - The development of new agricultural applications, including biodegradable materials and bio-pesticides, is highlighted as a means to promote green transformation in agriculture [11]. Group 3: Market Overview of Agricultural Bio-Manufacturing - As of February 9, 2025, there are 161 companies in the A-share market related to the "synthetic biology" concept, with a total market value of approximately 1.69 trillion yuan, averaging 10.5 billion yuan per company [15]. - The agricultural bio-manufacturing sector includes around 20 companies focusing on areas such as animal vaccines and feed additives, indicating a gradual industrial application of synthetic biology in agriculture [17]. - Key companies in this sector are noted for their focus on replacing feed, plant breeding, bio-pesticides, and precision farming, showcasing the diverse applications of synthetic biology in agriculture [17].

Core Insights - The report titled "Synthetic Biology Industry & Investment Strategy Research Report" provides a comprehensive analysis of the synthetic biology sector, covering technical pathways, market landscape, representative companies, industrial clusters, and policy trends [2]. Group 1: Company Overview - Zhejiang Jintou Shengyuan Equity Investment Co., Ltd. was established in June 2023 with a registered capital of 200 million yuan, serving as a market-oriented equity investment platform under the Zhejiang Provincial Innovation Investment Group [6]. - The company focuses on sectors such as new materials, new technologies, and biomedicine, with a total fund scale exceeding 10 billion yuan, aiming to enhance the operation of provincial government industrial funds [6][34]. Group 2: Market Dynamics - The global synthetic biology market has grown from $5.3 billion in 2018 to over $17 billion in 2023, with an average annual growth rate of 27%. It is projected to reach nearly $50 billion by 2028 [25]. - The Chinese market is expected to be approximately 10 billion yuan in 2024, continuing to grow to 12.406 billion yuan in 2025 [25]. Group 3: Technological Advancements - Shanghai Kasei Biotechnology Co., Ltd. has pioneered the large-scale production technology of bio-based long-chain dicarboxylic acid since 2003, breaking the monopoly of chemical synthesis [7]. - Ginkgo Bioworks has expanded its offerings into life science tools and services, integrating various foundational tools to assist downstream clients in producing desired biological products [14][15]. Group 4: Investment Strategies - The report emphasizes the importance of strategic partnerships and collaborations in the synthetic biology sector, highlighting the need for investment in innovative technologies and platforms to drive growth [19][25]. - The investment landscape is characterized by a shift from pure service models to integrated solutions that combine research services with product offerings, particularly in the context of AI and automation [15][16].

在全球推进绿色转型与"双碳"目标的战略背景下，生物基化学品与材料作为生物制造产业的核心支 柱，凭借原料可再生、全生命周期低碳环保等核心优势，正加速替代传统石油基产品，在包装、纺 织、汽车等领域展现出广阔应用前景，成为全球产业绿色转型的关键赛道。 我国高度重视该领域发展，将生物基新材料列为关键战略材料，多项产业扶持政策持续落地。然 而，产业仍面临包括综合成本竞争力、原料供应链稳定、产品性能优化及终端市场接受度等关键问 题。 基于此， 2026年3月31日-4月1日 ，"第五届中国合成生物学及生物制造大会"将在杭州举办，其中设 置 【 生物基化学品与材料专场】 ，旨在汇聚产学研用多方智慧，破解产业发展难题，助力生物基 化学品与材料产业高质量发展。 大会介绍 0 1 大会时间 | 2026年3月31日-4月1日 大会地点 | 杭州市 大会规模 | 1000人 主办单位 | synbio深波 承办单位 | 享融智云 媒体支持 | synbio新农食、synbio新美护、synbio新材料、生物制造圈、合成生物学俱乐部 扫码 免费 报名参会 ↓↓↓ 论坛设置 0 2 拟定话题 0 3 *以大会现场实际议程为准 会议路演 ...

新华财经上海2月4日电（记者王淑娟）人形机器人将组团上马年春晚，你最期待谁的表演？在"加快高 水平科技自立自强，引领发展新质生产力"的战略引领下，如何让前沿技术的"星火"淬炼为驱动产业升 级的"烈焰"？怎样让金融资源如涓涓细流般精准支持科技创新的每一个环节？作为我国科技创新与金融 改革的双高地，上海正探索构建覆盖企业全生命周期的多元化接力式的科技金融服务体系。近日，记者 调研走访上海多家科技企业，从具身智能到合成生物学，从实验室突破到产线满负荷运转，一幅科技、 产业、金融深度融合的图景徐徐展开。 擘画"AI+制造"新图景 弈柯莱是一家拥有先进合成生物学技术的生物智造企业，主要从事合成生物学方法的研发，并致力于将 其应用于规模化生产，总部和研发中心坐落于上海紫竹国家高新区，同时下设台州及重庆两个生产基地 和一个销售中心。截至目前，该公司已完成E轮融资。 "春节前夕订单爆满，我们的产线非常忙碌，公司自主研发的甜菊糖苷在茶饮、咖啡等饮料食品领域获 得了大批量订单。"弈柯莱财务总监、董事会秘书张莹告诉记者，目前弈柯莱的甜菊糖苷已获得国家卫 健委审批，并进入规模化生产阶段。 据弈柯莱联合创始人、首席科学家瞿旭东介绍，甜 ...

在全球推进绿色转型与"双碳"目标的战略背景下，生物基化学品与材料作为生物制造产业的核心支 柱，凭借原料可再生、全生命周期低碳环保等核心优势，正加速替代传统石油基产品，在包装、纺 织、汽车等领域展现出广阔应用前景，成为全球产业绿色转型的关键赛道。 我国高度重视该领域发展，将生物基新材料列为关键战略材料，多项产业扶持政策持续落地。然 而，产业仍面临包括综合成本竞争力、原料供应链稳定、产品性能优化及终端市场接受度等关键问 题。 基于此， 2026年3月31日-4月1日 ，"第五届中国合成生物学及生物制造大会"将在杭州举办，其中设 置 【 生物基化学品与材料专场】 ，旨在汇聚产学研用多方智慧，破解产业发展难题，助力生物基 化学品与材料产业高质量发展。 大会介绍 0 1 大会时间 | 2026年3月31日-4月1日 大会地点 | 杭州市 大会规模 | 1000人 主办单位 | synbio深波 承办单位 | 享融智云 媒体支持 | synbio新农食、synbio新美护、synbio新材料、生物制造圈、合成生物学俱乐部 扫码 免费 报名参会 ↓↓↓ 论坛设置 0 2 拟定话题 0 3 *以大会现场实际议程为准 会议路演 ...

Core Insights - The report titled "Synthetic Biology Industry & Investment Strategy Research Report" provides a comprehensive analysis of the synthetic biology sector, covering technical pathways, market landscape, representative companies, industrial clusters, and policy trends [2]. Group 1: Company Overview - Zhejiang Jintou Shengyuan Equity Investment Co., Ltd. was established in June 2023 with a registered capital of 200 million yuan, serving as a market-oriented equity investment platform under the Zhejiang Provincial Innovation Investment Group [6]. - The company focuses on sectors such as new materials, new technologies, and biomedicine, with a total fund scale exceeding 10 billion yuan, aiming to enhance the operation of provincial government industrial funds [6][34]. Group 2: Market Dynamics - The global synthetic biology market has grown from $5.3 billion in 2018 to over $17 billion in 2023, with an average annual growth rate of 27%. It is projected to reach nearly $50 billion by 2028 [25]. - The Chinese market is expected to reach approximately 10 billion yuan in 2024 and continue to grow to 12.406 billion yuan in 2025 [25]. Group 3: Technological Advancements - Shanghai Kasei Biotechnology Co., Ltd. has pioneered the large-scale production technology of long-chain dicarboxylic acids through biological methods, breaking the monopoly of chemical synthesis [7]. - Ginkgo Bioworks has expanded its offerings into life science tools and services, integrating various foundational tools to assist downstream clients in producing desired biological products [14][15]. Group 4: Investment Strategies - The report emphasizes the importance of strategic partnerships and collaborations in the synthetic biology sector, highlighting the need for investment in innovative technologies and platforms to drive growth [19][25]. - The investment landscape is characterized by a shift from pure service models to integrated solutions that combine research services with product offerings, particularly in the context of AI and automation [15][16].

事实上，在生物合成王浆酸领域，福瑞达不仅技术上实现了从0到1的突破，更打通了产业化路径，推动"山东好品"走向世界。 这一切的背后，是福瑞达多年来对成分创新的不懈坚持。正如鲁商集团总经理助理、福瑞达党委书记张岱州所言："成分创新是 国货实现弯道超车的关键。我们从透明质酸走向王浆酸，不仅是对中国成分的认知重塑，更是对'中国式抗衰'科技路径的坚定探 索。" 近日，山东省科学技术厅发布最新一批"山东好成果"名单，鲁商福瑞达医药股份有限公司（以下简称"福瑞达"）联合高校专家 团队研发的"生物合成王浆酸关键技术及产业化应用"项目榜上有名。彰显了这家具有"妆药同源"鲜明特色的山东国企，在合成 生物学领域的硬核科研实力。 20年攻坚撬动"液体黄金"产业化大门 这则低调的备案信息背后，昭示着振奋人心的突破：这不仅是中国首个获批用于化妆品的合成生物王浆酸原料，还宣告了全球 范围内首次实现该成分的规模化、绿色化生产，意味着王浆酸这种珍贵的生物活性物质，不再是传统的消耗性提取，而是高 效、可持续的"生物智造"。 王浆酸，具有"液体黄金"与"长寿因子"的美誉，是仅存在于蜂王浆中的稀有成分，含量仅为1.4—2.4%。科学研究表明，其在抗 ...